MBC-Related News from SABCS - Metastatic Breast Cancer Trial Talk

Conference Talk

The Annual San Antonio Breast Cancer Symposium was held on December 7-10, 2021. Read below for highlights from the meeting, including promising results about a new oral hormone therapy drug, a drug with activity against brain metastases in people with HER2-positive MBC, and genomic testing to guide MBC treatment choices.

Summary of Results From SABCS

Summary by Anne Loeser: Highlights from 2021 SABCS for People Living with MBC

Elacestrant (Oral Hormone Therapy Drug For Hormone Receptor-Positive MBC)
Fam-trastuzumab Deruxtecan-nxki (T-DXd) (For HER2-positive MBC, Including Brain Metastases)
Genomic Testing To Guide MBC Treatment Choices

Last Modified on January 12, 2022



for past articles or specific information.